Medicare drug rebates now apply to all Americans, not just seniors.
S. 1186 — Lower Drug Costs for Families Act · Filed by Catherine Cortez Masto (D-NV) · 13 cosponsors · Introduced Mar 27, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends Medicare's prescription drug inflation rebate program—which currently applies only to drugs covered under Medicare Part B (administered drugs) and Part D (retail drugs)—to also cover the same drugs when sold in the commercial (non-Medicare) market. It also shifts the baseline year for calculating inflation rebates backward from 2021 to 2016, meaning manufacturers must pay rebates if drug prices have risen faster than inflation since 2016 rather than since 2021. The effect is to lower drug prices for all Americans by requiring manufacturers to rebate price increases across all markets, not just Medicare.
Why we flagged it
The bill's core mechanism is to extend existing Medicare rebate authority to commercial markets and lengthen the inflation-measurement baseline. This is a regulatory expansion of price controls, not a new program or subsidy.
What the text implies
- Manufacturers may respond by raising list prices further upfront to offset expected rebates, shifting the burden to uninsured patients and those in the coverage gap before rebates are calculated.
- The 2016 baseline captures a decade of inflation, potentially triggering very large rebates on older drugs; manufacturers may discontinue low-margin drugs rather than pay rebates.
The full analysis lists 4 implications of this text.
Who stands to gain
patients and families (lower out-of-pocket drug costs); employers and health insurers (lower drug spending); Medicare program (lower Part B and Part D expenditures)